Details for New Drug Application (NDA): 216896
✉ Email this page to a colleague
NDA 216896 describes NIFEDIPINE, which is a drug marketed by Acella, Actavis Elizabeth, Chase Labs Nj, Heritage Pharma, Leading, Teva, Alembic, Alkem Labs Ltd, Aurobindo Pharma, Aurobindo Pharma Usa, Elite Pharm Solution, Martec Usa Llc, Mylan, Novast Labs, Osmotica Pharm Us, Par Pharm, Rising, Spil, Twi Pharms, Valeant Pharms North, Vitruvias, and Zydus Pharms, and is included in thirty NDAs. It is available from thirty-four suppliers. Additional details are available on the NIFEDIPINE profile page.
The generic ingredient in NIFEDIPINE is nifedipine. There are thirty-nine drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the nifedipine profile page.
The generic ingredient in NIFEDIPINE is nifedipine. There are thirty-nine drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the nifedipine profile page.
Summary for 216896
| Tradename: | NIFEDIPINE |
| Applicant: | Alembic |
| Ingredient: | nifedipine |
| Patents: | 0 |
| Formulation / Manufacturing: | see details |
Pharmacology for NDA: 216896
| Mechanism of Action | Calcium Channel Antagonists |
Medical Subject Heading (MeSH) Categories for 216896
Suppliers and Packaging for NDA: 216896
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| NIFEDIPINE | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 216896 | ANDA | Alembic Pharmaceuticals Limited | 46708-732 | 46708-732-31 | 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (46708-732-31) |
| NIFEDIPINE | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 216896 | ANDA | Alembic Pharmaceuticals Limited | 46708-732 | 46708-732-63 | 300 TABLET, EXTENDED RELEASE in 1 BOTTLE (46708-732-63) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 30MG | ||||
| Approval Date: | Nov 18, 2022 | TE: | AB2 | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 60MG | ||||
| Approval Date: | Nov 18, 2022 | TE: | AB2 | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 90MG | ||||
| Approval Date: | Nov 18, 2022 | TE: | AB2 | RLD: | No | ||||
Complete Access Available with Subscription
